COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Open Access
- 9 January 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (6) , 748-759
Abstract
Background: Studies have shown an increased risk of severe SARS-CoV-2–related (COVID-19) disease outcome and mortality for patients with cancer, but it is not well understood whether associations vary by cancer site, cancer treatment, and vaccination status. Methods: Using electronic health record data from an academic medical center, we identified a retrospective cohort of 260,757 individuals tested for or diagnosed with COVID-19 from March 10, 2020, to August 1, 2022. Of these, 52,019 tested positive for COVID-19 of whom 13,752 had a cancer diagnosis. We conducted Firth-corrected logistic regression to assess the association between cancer status, site, treatment, vaccination, and four COVID-19 outcomes: hospitalization, intensive care unit admission, mortality, and a composite “severe COVID” outcome. Results: Cancer diagnosis was significantly associated with higher rates of severe COVID, hospitalization, and mortality. These associations were driven by patients whose most recent initial cancer diagnosis was within the past 3 years. Chemotherapy receipt, colorectal cancer, hematologic malignancies, kidney cancer, and lung cancer were significantly associated with higher rates of worse COVID-19 outcomes. Vaccinations were significantly associated with lower rates of worse COVID-19 outcomes regardless of cancer status. Conclusions: Patients with colorectal cancer, hematologic malignancies, kidney cancer, or lung cancer or who receive chemotherapy for treatment should be cautious because of their increased risk of worse COVID-19 outcomes, even after vaccination. Impact: Additional COVID-19 precautions are warranted for people with certain cancer types and treatments. Significant benefit from vaccination is noted for both cancer and cancer-free patients.Keywords
All Related Versions
Funding Information
- National Science Foundation (NSF DMS 1712933)
- National Cancer Institute (CA 046592)
- Los Alamos National Laboratory (LDRD 20210761PRD1)
- Michigan Institute for Data Science, University of Michigan
- Rogel Cancer Center, University of Michigan
This publication has 66 references indexed in Scilit:
- Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient DataJCO Global Oncology, 2020
- Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort studyThe Lancet Oncology, 2020
- Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysisJournal of Hematology & Oncology, 2020
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyThe Lancet, 2020
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyThe Lancet, 2020
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakCancer Discovery, 2020
- Epidemiology of COVID-19Journal of Digestive Endoscopy, 2020
- Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study dataNature Biotechnology, 2013
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002
- Chemotherapy-induced immunosuppression.Environmental Health Perspectives, 1982